Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

March 19, 2024

Study Completion Date

February 28, 2029

Conditions
Superficial Basal Cell Carcinoma
Interventions
COMBINATION_PRODUCT

Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.

COMBINATION_PRODUCT

Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.

Trial Locations (18)

11209

The Narrows Institute for Biomedical Research and Education, Inc., Brooklyn

14564

Rochester Dermatologic Surgery, Victor

14623

Skin Search of Rochester, Inc, Rochester

23502

Virginia Clinical Research, Inc., Norfolk

29407

Clinical Research Center of the Carolinas, Charleston

32606

University of Florida Dept of Dermatology, Gainesville

33445

Dermatology Associates PA of the Palm Beaches, Delray Beach

46260

Laser and Skin Surgery Center of Indiana, Indianapolis

48202

Henry Ford Health System, Detroit

77056

Austin Institute for Clinical Research Inc., Houston

78660

Austin Institute for Clinical Research Inc., Pflugerville

80111

AboutSkin Research, LLC, Greenwood Village

84088

Jordan Valley Dermatology, West Jordan

85006

Medical Dermatology Specialists, Phoenix

85032

Alliance Dermatology & Mohs Center, Phoenix

92121

Cosmetic Laser Dermatology, San Diego

92708

First OC Dermatology, Fountain Valley

03756

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors
All Listed Sponsors
lead

Biofrontera Bioscience GmbH

INDUSTRY